6533b872fe1ef96bd12d30e2
RESEARCH PRODUCT
Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review.
Eduardo NúñezJuan SanchisPatricia PalauJulio NúñezEnrique SantasRafael De La EspriellaGema MiñanaPau LlàcerFrancisco J. ChorroVicent BodíJosep LupónAntoni Bayes-genissubject
Heart Failuremedicine.medical_specialtyClinical eventsbusiness.industryDisease progressionCarbohydratesSigns and symptomsmedicine.diseasePrognosisAntigenHeart failureCA-125 AntigenmedicineDisease ProgressionBiomarker (medicine)HumansNarrative reviewIn patientCardiology and Cardiovascular MedicineIntensive care medicinebusinessBiomarkersdescription
Congestion explains many of the signs and symptoms of acute heart failure (AHF) and disease progression. However, accurate quantification of congestion is challenging in daily practice. Antigen carbohydrate 125 (CA125) or mucin 16 (MUC16), a large glycoprotein synthesized by mesothelial cells, has emerged as a reliable proxy of congestion and inflammation in patients with heart failure. In AHF syndromes, CA125 is strongly associated with right-sided heart failure parameters and a higher risk of adverse clinical events beyond standard prognostic factors, including natriuretic peptides. Furthermore, CA125 has the potential for both monitoring and guide HF treatment following a decompensated HF event. The wide availability of CA125 in most clinical laboratories, together with its standardized measurement and reduced cost, makes this marker attractive for routine use in decompensated HF. Further research is required to understand better its biological role and its promising utility as a tool to guide decongestive therapy in HF. This article is protected by copyright. All rights reserved.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-07-20 | European journal of heart failureReferences |